Cardiac Safety Committee
Workshop
May 15-16, 2018
Boston, Massachusetts, USA
Langham Boston Hotel

Agenda
(Available presentations are linked next to the corresponding talk)

Day 1, May 15, 2017

8:30 a.m. – 10:30 a.m. Meeting Goals & Intro to Failure Modes:

- Building on our successes: Pushing the CV window – Brian Berridge – NTP, available online here
- Scoping/failure modes – to setup topics for the rest of the day – Jean-Pierre Valentin – UCB, available online here
- Systems Biology – how do we integrate and translate to arrive at meaningful understanding of results? – Matthew White – US FDA
- From in vitro cardiotoxicity screens to human population risk predictions: A case study of hazard, concentration-response, and population variability in the effects of 13 drugs – Ivan Rusyn – Texas A&M University (Slides available upon request, email Jennifer Pierson for details)

10:45 a.m. – 2:00 p.m. Exploring possible solutions

- Brief overview of the existing Committee portfolio. – Brian Berridge – NTP, available online here

- Using Networks to Link Genotype to Phenotype- John Quackenbush – Harvard University, available online here
- One Cell to Bind Them All: Bridging Functional and Structural Cardiotoxicity Assays for a More Comprehensive Risk Assessment – Mike Clements – Axion Biosystems, available online here
- Engineered 3D cardiac tissue platforms to assess contractility – Anant Chopra – Boston University, available online here.
A view from the CRACK-IT consortium: Integration of hiPSC-cardiomyocytes into drug screening and disease modelling – 
**Chris Denning – University of Nottingham**

Using human cardiomyocytes and bright-field imaging to finger-print different inotropic mechanisms of action – 
**Najah AbiGerges – Anabios, available online here**

Heart-on-Chip Technologies for *in vitro* Cardiomyocyte Assessment Studies - **Herdeline Ardoña - Wyss Institute, available online here**

3:00 p.m. – 5:00 p.m.  
Afternoon Discussion Groups:  
- Breakout into groups to ID gaps related to failure modes

**Day 2, May 16, 2017**

9:00 a.m. – 9:30 a.m.  
Review day 1 – what are the failure modes we want to consider, where are the gaps ID’ed from day 1 breakouts?

9:30 a.m. – 12:00 p.m.  
Review of existing projects that fit into this scheme  
- Cellular Systems – **Alexandre Ribeiro, available online here**  
- Biomarkers – **Eric Schultze and Marjory Brooks, available online here**  
- Math modeling – **Esther Bonetluz, available online here**  
- Stem Cell – **Gary Gintant, available online here**  
- Bridging Ion Channel and Myocyte Data – **Tim Strassmaier, available online here**

10:45 a.m. – 11:00 a.m.  
Cardiac Safety Committee Working Groups Breakouts

1:00 p.m. – 2:00 p.m.  
Report back from breakouts and discussion session

2:30 p.m. – 4:00 p.m.  
- What it means to have an effective in-vitro assay strategy? Which assays can be implemented for early CV de-risking and later stages of development? Perspectives on new Merck & Co.’s strategies including CiPA paradigm. – **Dr. Frederick Sannajust – Executive Director of Safety & Exploratory Pharmacology, Merck Research Laboratories**
• CRACK-IT – NC3Rs – implementation of these efforts – Anthony Holmes – NC3RS, available online here.

• Panel Discussion:
  o What additional partnerships or opportunities exist that can help us move in this direction?
  o Exploration of resourcing these efforts


4:00 p.m.  Wrap-Up, Brian Berridge, available online here

5:00 p.m.  Adjourn